MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
Rhea-AI Summary
MaxCyte (NASDAQ: MXCT) will release first quarter 2026 financial results after the U.S. market close on May 12, 2026. Company management will host a conference call at 4:30 p.m. Eastern Time. Investors must register online in advance. A live and archived webcast will be available on the Events section of the MaxCyte investor website at https://investors.maxcyte.com/.
Positive
- None.
Negative
- None.
News Market Reaction – MXCT
In the Apr 30 session, MXCT gained 7.63%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.7% during that session. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Earnings date announcement | Neutral | +5.0% | Set date and time for Q4 and full-year 2025 financial results call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date news on Feb 23, 2026 coincided with a positive +5.01% move, suggesting scheduling earnings calls has previously attracted investor interest.
Recent news shows a mix of operational and financial updates. The company last set an earnings date on Feb 23, 2026 for its Q4 and FY2025 report, which preceded a +5.01% move, indicating investors reacted constructively to that timing announcement. Since then, MXCT has reported weaker 2025 results, guidance for 2026, and leadership changes. Today’s notice sets expectations for Q1 2026 results, fitting into a pattern of regular financial disclosure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call Details
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing characterization assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on LinkedIn.
Investor Relations
Gilmartin Group
David Deuchler, CFA
ir@maxcyte.com
Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com
